Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Return on Capital Employed (2021 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Return on Capital Employed for 4 consecutive years, with 0.62% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Return on Capital Employed fell 22.0% year-over-year to 0.62%, compared with a TTM value of 0.62% through Jun 2025, down 22.0%, and an annual FY2023 reading of 0.37%, down 35.0% over the prior year.
  • Return on Capital Employed was 0.62% for Q2 2025 at Barinthus Biotherapeutics, down from 0.37% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.02% in Q3 2022 and bottomed at 0.62% in Q2 2025.
  • Average Return on Capital Employed over 4 years is 0.26%, with a median of 0.32% recorded in 2023.
  • The sharpest move saw Return on Capital Employed tumbled -42bps in 2023, then rose 3bps in 2024.
  • Year by year, Return on Capital Employed stood at 0.02% in 2022, then plummeted by -2481bps to 0.4% in 2023, then rose by 7bps to 0.37% in 2024, then tumbled by -67bps to 0.62% in 2025.
  • Business Quant data shows Return on Capital Employed for BRNS at 0.62% in Q2 2025, 0.37% in Q3 2024, and 0.4% in Q2 2024.